Please provide your email address to receive an email when new articles are posted on . Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new ...

Pairing a novel cytotoxic agent with bevacizumab (Avastin) failed to improve progression-free survival (PFS) versus standard therapy in older patients with metastatic colorectal cancer (mCRC) ...

Please provide your email address to receive an email when new articles are posted on . The addition of bevacizumab to trifluridine/tipiracil demonstrated a statistically significant and clinically ...

LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from ...

PARIS and PRINCETON, N.J., Jan. 17, 2023 /PRNewswire/ -- Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination ...

Trifluridine/tipiracil is indicated in European Union for the treatment of adult patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies ...

The US Food and Drug Administration (FDA) has approved the use of trifluridine and tipiracil (Lonsurf, Taiho Oncology) along with bevacizumab for patients with metastatic colorectal cancer (CRC) who ...

PRINCETON, N.J., Oct. 21, 2018 /PRNewswire/ -- Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan) and Servier jointly announced today the clinical data from the ...

Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial. This is an ASCO Meeting Abstract from the ...